Abbott Laboratories (ABTCL.SN)
Santiago - Santiago Delayed price. Currency in CLP
Add to watchlist
At close: 10:27AM CLT
| Previous close | 108,200.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 100,220.00 - 100,220.00 |
| 52-week range | 85,081.00 - 117,270.00 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 23,263.70 |
| EPS (TTM) | 4.31 |
| Earnings date | 18 Jul 2024 - 22 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAbbott Declares 402nd Consecutive Quarterly Dividend
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
ZacksAbbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.
PR NewswireAbbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and welln
© 2024 Yahoo. All rights reserved.